Sign In to Request a Protocol
Sign In to Request a Protocol

BPC-157 (10 mg Vial) Dosage Protocol

  • Table of Contents

BPC-157 Dosage Chart

BPC-157 is dosed at 200 mcg–600 mcg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

  • Reconstitute: Add 3.0 mL bacteriostatic water → 3.33 mg/mL concentration.
  • Typical daily range: 200–600 mcg once daily (gradual titration).
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a gastric protein sequence studied for tissue-healing and cytoprotective properties. Preclinical models demonstrate accelerated wound repair and anti-inflammatory activity, though human clinical data remain limited to early-phase safety trials and small case reports. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

  • Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

PhaseDaily Dose (mg)Units (per injection) (mL)
Weeks 1–2200 mcg (0.2 mg)6 units (0.06 mL)
Weeks 3–4400 mcg (0.4 mg)12 units (0.12 mL)
Weeks 5–8+600 mcg (0.6 mg)18 units (0.18 mL)

Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per-injection units well above 5 for better accuracy. Dosing is extrapolated from preclinical models; human clinical validation remains limited.

Reconstitution Steps
  • 1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  • 2. Inject slowly down the vial wall; avoid foaming.
  • 3. Gently swirl/roll until dissolved (do not shake).
  • 4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
  • Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
  • Peptide Vials (BPC-157, 10 mg each):
  • 8 weeks ≈ 3 vials (25.2 mg used)
  • 12 weeks ≈ 5 vials (42 mg used)
  • 16 weeks ≈ 6 vials (58.8 mg used)
  • Insulin Syringes (U-100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
  • 12 weeks (5 vials): 15 mL → 2 × 10 mL bottles
  • 16 weeks (6 vials): 18 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
  • 16 weeks: 224 swabs → recommend 3 × 100-count boxes
  • Protocol Overview
Concise summary of the once-daily regimen.
  • Goal: Support tissue-healing and recovery processes based on preclinical evidence.
  • Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
  • Dose Range: 200–600 mcg daily with gradual titration.
  • Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
  • Dosing Protocol
Suggested daily titration approach.
  • Start: 200 mcg daily; increase by ~200 mcg every 2 weeks as tolerated.
  • Target: 400–600 mcg daily by Weeks 5–8+.
  • Frequency: Once per day (subcutaneous).
  • Cycle Length: 8–12 weeks; optional extension to 16 weeks.
  • Timing: Any consistent time; rotate injection sites.
  • Storage Instructions

Proper storage preserves peptide quality.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • Important Notes
Practical considerations for consistency and safety.
  • Use new sterile insulin syringes for each injection; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose and site rotation to maintain consistency.
  • BPC-157 human data are preliminary; clinical decisions should involve qualified healthcare providers.
  • How This Works

BPC-157 is a synthetic peptide corresponding to a partial sequence of human gastric juice protein. Preclinical studies suggest it modulates nitric oxide pathways and growth-factor expression to promote angiogenesis and collagen deposition in damaged tissues. Animal models report accelerated healing of gut, tendon, ligament, and muscle injuries. A Phase I oral safety trial has been completed, and a small human case series reported improvements following intra-articular administration; however, large-scale controlled human efficacy data are not yet available.

  • Potential Benefits & Side Effects
Observations from preclinical and early clinical literature.
  • Supports tissue repair in gut, tendon, muscle, and skin injury models (animal data).
  • Demonstrates anti-inflammatory and cytoprotective properties in preclinical settings.
  • Phase I safety studies report good tolerability with no serious adverse events at tested doses.
  • Occasional mild injection-site reactions (redness, itch) may occur with subcutaneous administration.
  • Long-term human safety and efficacy remain under investigation.
  • Lifestyle Factors
Complementary strategies for best outcomes.
  • Support recovery with adequate protein intake and micronutrient-rich foods.
  • Balance activity and rest to allow tissue adaptation without overuse.
  • Prioritize sleep and stress management to enhance natural healing processes.
  • Consult qualified healthcare providers for injury-specific rehabilitation guidance.
  • Injection Technique

General subcutaneous guidance from clinical best-practice resources.

  • Clean the vial stopper and injection site with alcohol; allow to dry completely.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
  • Do not aspirate for subcutaneous injections; inject slowly and steadily.
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
  • Discard used syringes immediately in a sharps container per WHO guidelines.
  • Recommended Source
We recommend Vitality Labs Peptides for high-purity 5-Amino-1MQ (10 mg).

Why Vitality Labs Peptides?

  • High-purity, third-party-tested lots with batch COAs.
  • Consistent, ISO-aligned handling and documentation.
  • Reliable fulfillment to maintain cold-chain integrity.
Contact on Telegram
  • Important Note
This content is for educational purposes only and is not medical advice, diagnosis, or treatment. BPC-157 remains investigational with limited human clinical data. For research use only. Not for human consumption.
  • References

Explore related research dosage protocols and background reading for BPC-157 + TB-500.

Journal of Pharmacological Sciences

— Klicek R et al. BPC-157 promotes colocutaneous fistula healing via NO-system modulation (rat model)
More Info

Pharmaceuticals (MDPI)

— Józwiak M et al. Multifunctionality and possible medical application of BPC-157: literature and patent review (2025)
More Info

Current Pharmaceutical Design (PMC)

— Sikiric P et al. BPC-157 stable gastric pentadecapeptide: novel therapy for wound healing and tissue repair
More Info

Life Sciences

— Seiwerth S et al. BPC-157 and standard angiogenic growth factors: gastrointestinal tract healing and beyond
More Info

HSS Journal (PubMed)

— Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: systematic review (2025)
More Info

Journal of Orthopaedic Research

— Chang CH et al. BPC-157 promotes tendon-to-bone healing in a rat rotator cuff model
More Info

WHO (NCBI Bookshelf)

— Guideline on safety-engineered syringes for IM, ID, and SC injections in health care settings (2016)
More Info

Johns Hopkins Arthritis Center

— How to give a subcutaneous injection (patient education resource)
More Info

ClinicalTrials.gov

— NCT02637284: PCO-02 Phase I safety and pharmacokinetics trial of oral BPC-157
More Info

CDC

— Vaccine administration: subcutaneous route (angle/site; no aspiration)
More Info

Subcutaneous Drug Injection Review (PMC)

— Pharmacologic considerations of the subcutaneous route
More Info

World Journal of Gastroenterology (PMC)

— Sikiric P et al. Pentadecapeptide BPC-157: from GI tract to whole body healing
More Info

Vitality Lab Peptides

— BPC-157 (10 mg) product page (quality and batch documentation) View Source
More Info